A randomized controlled trial to assess the efficacy of 12-hour magnesium sulphate therapy compared to 24-hour regimen on maternal outcome among patients with eclampsia admitted in a tertiary care centre

Authors

  • Ankita Bhattacharjee Department of Obstetrics and Gynaecology, Agartala Govt. Medical College and GBP Hospital, Agartala, Tripura, India
  • Jayanta Ray Department of Obstetrics and Gynaecology, Agartala Govt. Medical College and GBP Hospital, Agartala, Tripura, India
  • Salilbindu Chakrabarti Department of Obstetrics and Gynaecology, Agartala Govt. Medical College and GBP Hospital, Agartala, Tripura, India
  • Debasis Ray Department of Pharmacology, Agartala Govt. Medical College and GBP Hospital, Agartala, Tripura, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241957

Keywords:

Recurrent seizure, MgSO4, Maternal morbidity

Abstract

Background: Magnesium sulphate (MgSO4) is the most popular anti-convulsant drug for treatment of eclampsia. Pritchard regimen is the most widely used regime worldwide where maintenance dose of MgSO4 is administered for 24-hour after delivery or last fit (whichever is later). As the duration of MgSO4 therapy increases, the incidence of adverse effects also increases. Therefore, the present study has been conducted to compare the maternal outcome with decreased duration of MgSO4 therapy for 12-hour with that of 24 hours for patients with eclampsia.

Methods: It was an experimental study which was performed as a single centered, open labelled hospital based randomized control trial. It was conducted for 2 years (December 2019 to November 2021) among the patients of eclampsia admitted at department of obstetrics and gynaecology, AGMC and GBPH.

Results: No cases of recurrent seizures in either group with additional benefit of lesser adverse effect of toxicity of MgSO4 in the 12-hour group.

Conclusions: In the present study, it has been seen that 12-hour MgSO4 maintenance therapy is as efficacious as standard 24 hours therapy in controlling seizure as there was no case of recurrent seizure in either group.

References

Vigil-De Gracia P. Maternal deaths due to eclampsia and HELLP syndrome. Int J Gynaecol Obstet. 2009;104(2):90-4.

Ranganna H, Saha SC, Thami MR, Kumar P. Prophylactic magnesium sulphate in severe preeclampsia-Loading dose only vs conventional 24 hour therapy of modified Pritchard’s regime A randomized trial. IOSR J Pharm 2014;4(6):39-47.

Witlin AG, Sibai BM. Randomized trials for prevention and treatment of eclamptic convulsions. In: Sibai BM, ed. Hypertensive Disorders in Women. Philadelphia: WB Saunders. 2001;221-7.

Euser AG, Cipolla MJ. Magnesium sulphate treatment for the prevention of eclampsia: A brief review. Stroke. 2009;40(4):1169-75.

Vigorito C, Giordano A, Ferraro P. Haemodynamic effects of magnesium sulfate on the normal human heart. Am J Cardiol. 1990;65:709-12.

Sadeh M. Action of Magnesium sulphate in the treatment of preeclampsia and eclampsia. Stroke. 1989;20:1273-5

Sunitha HB, Parikh S, Waikar MR, Panchgar V, Akshaya, Shetti AN. Comparison of single loading dose magnesium sulphate regimen with low dose magnesium sulphate regimen in the treatment of eclampsia. Indian J Obstetr Gynecol Res. 2017;4(4):338-42.

Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for the treatment of eclampsia: Evaluation of 245 cases. Am J Obstet Gynaecol. 1984;148:951-63.

Ekele BA, Muhammed D, Bello LN, Namadina IM. Magnesium sulphate therapy in eclampsia: the Sokoto (ultra short) regimen. BMC Res Notes. 2009;2:165.

Leal NV, Amorim MM, Franca-Neto AH, Bárbara VRC, Ana PRLA, Melania MRA. 12-hour compared with 24-hour postpartum magnesium sulfate therapy in preeclampsia: a randomized clinical trial. Obstet Gynecol. 2014;123(3):64S.

Nautiyal R, Srivastava A, Chauhan N, Nautiyal HK. Feasibility of low dose magnesium sulphate for eclampsia–a randomized study. Indian J Obstetr Gynecol Res. 2016;3(2):121-5.

Anjum S, Goel N, Sharma R, Mohsin Z, Garg N. Maternal outcomes after 12 hours and 24 hours of magnesium sulfate therapy for eclampsia. Int J Gynecol Obstetr. 2016;132(1):68-71.

Vigil-De Gracia P, Ramirez R, Durán Y, Quintero A. Magnesium sulfate for 6 vs 24 hours post delivery in patients who received magnesium sulfate for less than 8 hours before birth: a randomized clinical trial. BMC Pregnancy Childbirth. 2017;17(1):1-6.

Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359:1877-90.

Downloads

Published

2024-07-09

How to Cite

Bhattacharjee, A., Ray, J., Chakrabarti, S., & Ray, D. (2024). A randomized controlled trial to assess the efficacy of 12-hour magnesium sulphate therapy compared to 24-hour regimen on maternal outcome among patients with eclampsia admitted in a tertiary care centre. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20241957

Issue

Section

Original Research Articles